Ovarian hyperstimulation syndrome most often occurs as an iatrogenic complication of ovarian stimulation treatments for in vitro fertilization; the incidence of severe forms ranges from 0.5 to 5% (Delvigne and Rozenberg, 2002). The clinical manifestations vary from abdominal ... Ovarian hyperstimulation syndrome most often occurs as an iatrogenic complication of ovarian stimulation treatments for in vitro fertilization; the incidence of severe forms ranges from 0.5 to 5% (Delvigne and Rozenberg, 2002). The clinical manifestations vary from abdominal distention and discomfort to potentially life-threatening, massive ovarian enlargement and capillary leak with fluid sequestration. Pathologic features of the syndrome, whether spontaneous or iatrogenic, include the presence of multiple serous and hemorrhagic follicular cysts lined by luteinized cells, a condition called hyperreactio luteinalis (Scully et al., 1998).
In a 25-year-old woman of Moroccan origin who had 4 of 5 spontaneous pregnancies complicated by ovarian hyperstimulation syndrome, Vasseur et al. (2003) identified heterozygosity for a mutation in the FSHR gene (T449I; 136435.0008). Two of the patient's ... In a 25-year-old woman of Moroccan origin who had 4 of 5 spontaneous pregnancies complicated by ovarian hyperstimulation syndrome, Vasseur et al. (2003) identified heterozygosity for a mutation in the FSHR gene (T449I; 136435.0008). Two of the patient's 4 sisters reported similar histories, and the T449I mutation was identified in both; T449I was not identified in 1 of the patient's unaffected sisters. In a woman with spontaneous ovarian hyperstimulation syndrome previously described by Olatunbosun et al. (1996), Smits et al. (2003) identified a mutation in the FSHR gene (D567N; 136435.0009). Kaiser (2003) reviewed the pathogenesis of ovarian hyperstimulation syndrome and the mechanism by which mutations in the FSH receptor result in the disorder, with explanatory diagrams. In a 21-year-old Turkish woman who developed OHSS in the first trimester of her first pregnancy, previously described by Cepni et al. (2006), De Leener et al. (2008) identified heterozygosity for a mutation in the FSHR gene (S128Y; 136435.0013). Her beta-HCG level was normal for a 3-month singleton pregnancy, and her TSH (see 118850) level was normal; her symptoms regressed during the second and third trimester with conservative medical treatment, and resolved postpartum.